Page 84

Junio 2017

ARTÍCULO DE REVISIÓN Terapia hormonal de la menopausia y calidad de vida - J. E. Blümel et al 12. Thurston RC, Bromberger JT, Joffe H, Avis NE, Hess R, Crandall CJ, et al. Beyond frequency: who is most bothered by vasomotor symptoms? Menopause 2008; 15 (5): 841-7. 13. Murphy PJ, Campbell SS. Sex hormones, sleep, and core body temperature in older postmenopausal women. Sleep 2007; 30 (12): 1788-94. 14. Rossmanith WG, Ruebberdt W. What causes hot flushes? 764 The neuroendocrine origin of vasomotor symptoms in the menopause. Gynecol Endocrinol 2009; 25 (5): 303-14. 15. Warren MP. Missed symptoms of menopause. Int J Clin Pract 2007; 61 (12): 2041-50. 16. Savolainen-Peltonen H,  Hautamäki H,  Tuomikoski P, Ylikorkala O, Mikkola TS. Health-related quality of life in women with or without hot flashes: a randomized placebo-controlled trial with hormone therapy. Menopause  2014; 21 (7): 732-9. 17. Herber-Gast G, Brown WJ, Mishra GD. Hot flushes and night sweats are associated with coronary heart disease  risk in midlife: a longitudinal study. BJOG 2015; 122 (11): 1560-7. 18. Ojaniatva A, Makinen J, Helenius H, Korkeiia K, Sundell J, Rautava P. Sexual activity and perceived health among Finnish middle-aged women. Health Qual Life Outcomes 2006; 4: 29.    19. Collaborative Group for Research of the Climacteric in Latin America (REDLINC). Sexual dysfunction in middle aged women: a multicenter Latin American study using the Female Sexual Function Index. Menopause 2009; 16 (6): 1139-48. 20. Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, et al. PRO Harmonization Group. Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health 2003; 6 (5): 522-31. 21. Blümel JE, Lavín P, Vallejo MS, Sarrá S. Menopause or climacteric, just a semantic discussion or has it clinical implications? Climacteric 2014; 17 (3): 235-41. 22. Taylor VH, Forhan M, Vigod SN, McIntyre RS, Morrison KM. The impact of obesity on quality of life. Best Pract Res Clin Endocrinol Metab 2013; 27 (2): 139-46. 23. Morris AA, Ahmed Y, Stoyanova N, Hooper WC, De Staerke C, Gibbons G, et al. The association between depression and leptin is mediated by adiposity. Psychosom Med 2012; 74 (5): 483-8. 24. Rossetti C, Halfon O, Boutrel B. Controversies about a common etiology for eating and mood disorders. Front Psychol 2014; 5: 1205. 25. Clegg DJ, Brown LM, Woods SC, Benoit SC. Gonadal hormones determine sensi-tivity to central leptin and insulin. Diabetes 2006; 55 (4): 978-87. 26. Brown LM, Clegg DJ. Central effects of estradiol in the regulation of adiposity. J Steroid Biochem Mol Biol 2010; 122 (1-3): 65-73. 27. Blümel JE, Chedraui P, Aedo S, Fica J, Mezones-Holguín E, Barón G, et al. Obesity and its relation to depressive symptoms and sedentary lifestyle in middle-aged women. Maturitas 2015; 80 (1): 100-5. 28. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2001; 4 (1): 58-74. 29. Pitkin J, Smetnik VP, Vadász P, Mustonen M, Salminen K, Ylikangas S; Indivina 321 Study Group. Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women. Menopause Int 2007; 13 (3): 116-23. Rev Med Chile 2017; 145: 760-764


Junio 2017
To see the actual publication please follow the link above